FY2027 EPS Estimates for Journey Medical Cut by B. Riley

Journey Medical Co. (NASDAQ:DERM) – Equities research analysts at B. Riley decreased their FY2027 earnings per share (EPS) estimates for Journey Medical in a note issued to investors on Thursday, March 27th. B. Riley analyst K. Patel now anticipates that the company will post earnings of $0.31 per share for the year, down from their previous forecast of $0.39. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM) last announced its earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The business had revenue of $14.30 million for the quarter, compared to analysts’ expectations of $14.21 million.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research report on Thursday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.67.

Journey Medical Price Performance

Shares of NASDAQ:DERM opened at $5.90 on Monday. The firm’s 50 day moving average price is $5.14 and its 200-day moving average price is $5.18. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The stock has a market capitalization of $123.25 million, a PE ratio of -6.28 and a beta of 0.97. Journey Medical has a twelve month low of $3.20 and a twelve month high of $6.89.

Hedge Funds Weigh In On Journey Medical

A number of hedge funds have recently modified their holdings of the company. Tang Capital Management LLC bought a new stake in shares of Journey Medical during the 4th quarter valued at $6,747,000. PVG Asset Management Corp raised its holdings in Journey Medical by 5.7% during the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after acquiring an additional 9,005 shares during the period. Geode Capital Management LLC lifted its position in shares of Journey Medical by 13.5% in the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after acquiring an additional 12,882 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Journey Medical in the fourth quarter worth about $174,000. Finally, Kovitz Investment Group Partners LLC grew its position in shares of Journey Medical by 112.9% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock worth $97,000 after purchasing an additional 13,105 shares in the last quarter. 7.25% of the stock is currently owned by institutional investors.

Insider Activity

In other Journey Medical news, CEO Claude Maraoui sold 18,147 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total transaction of $93,094.11. Following the sale, the chief executive officer now owns 2,092,874 shares in the company, valued at approximately $10,736,443.62. This trade represents a 0.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 105,831 shares of company stock valued at $536,622 in the last ninety days. Corporate insiders own 13.16% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.